JAMA Network January 31, 2024
Anyone who watches television has probably seen the Pfizer commercial with the tagline, “If it’s COVID, Paxlovid.”
That might be a catchy slogan, but, apparently, a lot of people aren’t getting the message.
The US Food and Drug Administration (FDA) approved Paxlovid last May for the treatment of mild to moderate COVID-19 in adults who are at risk of progression to severe disease. But it has been available since early 2022 under Emergency Use Authorization (EUA) from the FDA for treating COVID-19 in people 12 years or older. A dose of Paxlovid consists of 2 pills of the protease inhibitor nirmatrelvir and 1 pill of ritonavir, which boosts nirmatrelvir’s concentration in plasma to the target therapeutic range by slowing its...
Today's Sponsors
Today's Sponsor